INDEX cost analysis

NIST. 2006b. Life-Cycle Cost Analysis Tool for Chem/Bio Protection of Buildings. Accessed on March 15, 2007, at http //www2.bfrl.nist.gov/software/LCCchembio/index.htm. 

No attempt was made to define an end of service Ufe as this was used as part of a life-cycle cost analysis study where repair or rehabilitation was conducted according to the minimum cost criterion. It was suggested that the condition index should never exceed 45%. 

Failure Mode and Costs Analysis. Failure Mode and Cost Analysis (Figure 2) applied to the omission of an activity in the Integrated Management System enables the systematic consideration of the failure modes that may result from the described omission and the evaluation of the probability and cost effective of this failure form. The P Index (on a scale of 1 to 10), called rate of occurrence, is assigned to the probability occurrence of the failure form. The C Index (on a scale of 1 to 10), called cost index is assigned to the effective failure cost. The product of both indices is called cost priority number (CPN). Value of CPN identifies the significant failure forms. The cost of a failure form will be the product of the failure mode probability and the effective failure cost. 

An effective HE or cost-effectiveness analysis is designed to answer certain questions, such as Is the treatment effective What will it cost and How do the gains compare with the costs By combining answers to all of these questions, the technique helps decision makers weigh the factors, compare alternative treatments, and decide which treatments are most appropriate for specific situations. Typically, one chooses the option with the least cost per unit of measure gained the results are represented by the ratio of cost to effectiveness (C E). With this type of analysis, called a cost-effectiveness analysis (CEA), various disease end points that are affected by therapy (risk markers, disease severity, death) can be assessed by corresponding indexes of therapeutic outcome (mmHg blood pressure reduction, hospitalizations averted, life years saved, respectively). It is beyond the scope of this chapter to elaborate further on principles of cost-effectiveness analyses. A number of references are available for this purpose [11-13]. 

The final question asks about the validity of the conclusions drawn by the study authors. Were the conclusions based on some overall index or ratio of costs to consequences, and was the index interpreted intelligently Did the study authors provide benchmarks to aid in the interpretation of the study, and was the robustness of the conclusions discussed in light of results of the sensitivity and/or statistical analyses Was subgroup analysis undertaken where relevant Were the results compared with those of others who have investigated the same question Were the limitations of the study and the gen-eralisability of the results discussed Were other relevant factors in the decision to adopt the intervention discussed (e.g. distribution, ethics) And... 

All NSAIDs, including aspirin, are about equally efficacious with a few exceptions—tolmetin seems not to be effective for gout, and aspirin is less effective than other NSAIDs (eg, indomethacin) for ankylosing spondylitis. Thus, NSAIDs tend to be differentiated on the basis of toxicity and cost-effectiveness. For example, the gastrointestinal and renal side effects of ketorolac limit its use. Fries et al (1993), using a toxicity index, estimated that indomethacin, tolmetin, and meclofenamate were associated with the greatest toxicity, while salsalate, aspirin, and ibuprofen were least toxic. The selective COX-2 inhibitors were not included in this analysis. 

Using this correlation we can impute crude oil price corresponding to a particular construction cost index. Using the 2007 value for the construction cost implies an equivalent oil price of 70 per barrel. This is used as the base price for oil and derivatives in the analysis. 

In financial analysis two final indices are available Conventional Safety Cost Index (CSCI) which is the ratio of conventional safety measures of the system over the probable loss cost, and Inherent Safety Cost Index (ISCI) which is the relative amount of the cost of inherent safety measures added to the system to the loss cost (Khan and Amyotte, 2004). Smaller ISCI in comparison to CSCI shows enviable impact of safety features on safety costs. In other words the smaller the ISCI/CSCI fraction the better the response. 

The key to a successful indexing is not a complete absence of impurity peaks (a few may be present) but it is the accuracy with which peak positions have been determined and the absence of significant systematic errors. Yet another important piece of advice, given in the manual, should always be followed do not waste computer time on bad data. Since the cost of computer time continuously lowers, but the cost of labor continuously rises, this statement could be rephrased do not waste your time on bad data. The latter is indeed applicable to any type of data analysis. 

This method of analysis relies on the same chemical principles as the determination by TLC, except that the efficiency (and the cost) of the technique has increased greatly. Instead of the R value, the retention time of the drug is measured and related to P by equations similar to equation (2.5) for TLC. The retention time, as its name suggests, is the time taken for the sample to elute from the HPLC column. The major drawback with using this technique to determine P is detecting the drug if it does not possess a chromophore, when a UV detector cannot be used. In cases like this, use must be made of an HPLC system connected to a refractive index (RI) detector or an electrochemical detector (ECD). 

In the ideal study, the results of aU patients tested with the test under evaluation are contrasted with the results of a single reference standard. If fewer than all patients are verified with the reference standard, then partial verification exists, and verification bias may occur if the selection of subjects for reference testing is not purely random. For example, if selection is associated with the outcome of the index test, or the strength of prior suspicion, or both, then verification bias is certain. In a typical case, some patients with negative test results (test-negatives) are not verified by the reference standard if this involves a costly or invasive procedure, and these patients are not included in the analysis. This may result in an underestimation of the number of false-negative results. 

The CUA is a form of cost-effectiveness analysis in which the health outcomes are measured in terms of quality-adjusted life-years (QALYs) gained. The QALY is a measure that associates quantity of life (for example survival data and life expectancy) with quality of life, by amalgamating them into a single index. One QALY is equal to a year of full life quality. Because of its universal denominator which allows comparisons across divergent areas, CUA is a tool that can (in theory) be used by policy makers... 

---